<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00934726</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-NAT-SER-2008/1</org_study_id>
    <nct_id>NCT00934726</nct_id>
  </id_info>
  <brief_title>Non-interventional Open Label Study to Investigate the Effect of Quetiapine XR on Patient Satisfaction and Quality of Life in Patients With Schizophrenia</brief_title>
  <acronym>PASQAL</acronym>
  <official_title>Patient Satisfaction and Quality of Life Under Treatment With Seroquel XR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since subjective well-being and quality of life (QoL) are increasingly being recognized as&#xD;
      important treatment outcomes in patients with schizophrenia (Hofer et al., 2004; Becker et&#xD;
      al., 2005), the aim of this study is to investigate the effect of treatment with quetiapine&#xD;
      XR on these parameters in the acute hospital and the subsequent ambulant care setting. The&#xD;
      study is planned to be conducted in 15 centers all over Austria and, overall, about 150&#xD;
      inpatients with a ICD-10 diagnosis of acute schizophrenia are planning to be enrolled. The&#xD;
      duration of the whole trial will be approximately 4 months, whereas 2 visits during&#xD;
      hospitalization and two further visits after discharge will be scheduled. At each visit,&#xD;
      adverse events and safety parameters, patient satisfaction and effectiveness of the current&#xD;
      treatment, as well as concomitant medication and dosing schedules will be assessed and&#xD;
      documented.In addition to that, the patients' overall satisfaction with antipsychotic therapy&#xD;
      and their current quality of life will be determined using a QoL questionnaire, focussing on&#xD;
      the subjective experience with quetiapine XR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Subject wellbeing under Neuroleptics scale (Quality of Life)</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BPRS (Brief Psychiatric Rating Scale)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI (Clinical Global Impression)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All adverse events occurring during the study will be documented</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Quality of Life in Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1 group, schizophrenia patients</arm_group_label>
    <description>Patients with schizophrenia according to ICD-10(diagnostic and statistical manual of mental disorders)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The psychiatrists according to inclusion criteria select patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult schizophrenia patients&#xD;
&#xD;
          -  Inclusion according to Summary of product characteristics&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis other than schizophrenia&#xD;
&#xD;
          -  Patients for which Seroquel XR is not registered (pregnant women, children and&#xD;
             adolescentsâ€¦)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siegfried Kasper, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AKH Vienna</affiliation>
  </overall_official>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>September 22, 2011</last_update_submitted>
  <last_update_submitted_qc>September 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of Life</keyword>
  <keyword>Patient satisfaction</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Investigate quality of life in schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

